AFC-HD AMS Life Science Co., Ltd.
2927.T · JPX
8/31/2025 | 8/31/2024 | 8/31/2023 | 8/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.53 | 0.70 | 0.20 | -0.29 |
| FCF Yield | -14.53% | -15.93% | -9.61% | 4.94% |
| EV / EBITDA | 6.58 | 7.24 | 7.55 | 7.64 |
| Quality | ||||
| ROIC | 3.85% | 3.20% | 3.40% | 1.94% |
| Gross Margin | 33.59% | 34.76% | 36.45% | 37.30% |
| Cash Conversion Ratio | 1.23 | 0.81 | 0.56 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.48% | 9.49% | 4.57% | 28,437,385.63% |
| Free Cash Flow Growth | 6.15% | -73.74% | -301.03% | -74.44% |
| Safety | ||||
| Net Debt / EBITDA | 3.41 | 3.46 | 3.23 | 2.94 |
| Interest Coverage | 11.83 | 18.92 | 28.43 | 17.62 |
| Efficiency | ||||
| Inventory Turnover | 3.09 | 3.29 | 3.73 | 3.87 |
| Cash Conversion Cycle | 89.94 | 78.65 | 65.00 | 48.62 |